Celebrex Polyp Trials Get Added Weight With Vioxx Withdrawal
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer is pointing to two trials with designs similar to Merck's APPROVe study as evidence of Celebrex' long-term efficacy. The Celebrex studies "have not shown any signficant safety issues and are expected to continue to completion," the company says.